Systolic blood pressure targets after successful endovascular thrombectomy: a network meta-analysis of randomized controlled trials.

Neurol SciSep 29, 2026 (epub)
Clinical ResearchNeurologyEmergency Medicine

Jiarong Zhu, Mu He, Yuyan Lu et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated the impact of different systolic blood pressure (SBP) targets on outcomes after endovascular thrombectomy in eight studies. The analysis found that an SBP target of < 180 mmHg was associated with the highest likelihood of functional independence (SUCRA = 87.3%). Lower targets of < 140 mmHg and < 120 mmHg correlated with worse outcomes.

Key findings

  • < 180 mmHg SBP target ranked highest for functional independence (SUCRA = 87.3%).
  • < 140 mmHg target had an odds ratio of 1.65 for worse outcomes.
  • < 120 mmHg target had an odds ratio of 1.75 for worse outcomes.
  • Higher actual SBP (117-139 mmHg) was associated with increased odds of functional independence (OR = 1.028).

Why it matters

Understanding optimal SBP targets post-thrombectomy is crucial for improving patient outcomes. This study suggests that maintaining higher SBP levels may enhance functional independence, guiding clinicians in managing blood pressure after such interventions.

Source

PubMed · PMID 42809028

Published in Neurol Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.